Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential

Mol Cancer. 2022 Sep 13;21(1):179. doi: 10.1186/s12943-022-01650-5.

Abstract

Mesenchymal stem cells (MSCs) are multipotent stromal cells that can be obtained from various human tissues and organs. They can differentiate into a wide range of cell types, including osteoblasts, adipocytes and chondrocytes, thus exhibiting great potential in regenerative medicine. Numerous studies have indicated that MSCs play critical roles in cancer biology. The crosstalk between tumour cells and MSCs has been found to regulate many tumour behaviours, such as proliferation, metastasis and epithelial-mesenchymal transition (EMT). Multiple lines of evidence have demonstrated that MSCs can secrete exosomes that can modulate the tumour microenvironment and play important roles in tumour development. Notably, very recent works have shown that mesenchymal stem cell-derived exosomes (MSC-derived exosomes) are critically involved in cancer resistance to chemotherapy agents, targeted-therapy drugs, radiotherapy and immunotherapy. In this review, we systematically summarized the emerging roles and detailed molecular mechanisms of MSC-derived exosomes in mediating cancer therapy resistance, thus providing novel insights into the clinical applications of MSC-derived exosomes in cancer management.

Keywords: Cancer; Exosome; Mesenchymal stem cell; Therapy resistance.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes
  • Exosomes* / metabolism
  • Humans
  • Mesenchymal Stem Cells* / metabolism
  • Neoplasms* / metabolism
  • Neoplasms* / therapy
  • Tumor Microenvironment